Answers are grounded in this paper and cite their sources.
SUMMARY Uncontrolled hemorrhage is the second leading cause of death from trauma. Most critically ill trauma patients suffer profound bleeding accompanied by systemic coagulopathy. The compassionate use of rFVIIa for uncontrolled hemorrhage was approved by the ethical committee of the Israeli Ministry of Health in late 1999. This manuscript reviews the published results of the first 19 Israeli trauma patients and the recent case series by Dutton and colleagues analyzing the early experience in critically ill trauma patients treated in Baltimore, MD, USA. Patients'survival was affected by severity of injury, the degree of coagulopathy prior to the drug's administration, and by coexistence of acidosis. In conclusion, the use of rFVIIa is currently recommended in massively bleeding patients, along with conventional surgical and hemostatic techniques. For optimal results, maximal correction of acidosis and coagulation parameters is advised prior to the drug's administration. Prospective, randomized placebo‐controlled trials of rFVIIa in traumatic injury are warranted.
No takes yet. Share an insight, caveat, or question.
Gili Kenet (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: